Screening for compounds that modulate epigenetic regulation of the transcriptome: An overview

Journal of Biomolecular Screening

Volumn 16, Issue 10, 2011, Pages 1137-1152

  Eglen, Richard M ^a   Reisine, Terry ^b  

^a Corning Life Sciences ^*  (United States)

^b NONE

Author keywords

acetylation; CpG islands; methylation; posttranslational modification

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 8 QUINOLINOL; AMINE OXIDASE (FLAVIN CONTAINING); AZACITIDINE; CARBOPLATIN; CISPLATIN; DEPSIPEPTIDE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; GEMCITABINE; GEMTUZUMAB; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; IMATINIB; LENALIDOMIDE; MG 98; MOCETINOSTAT; N PHTHALOYLTRYPTOPHAN; PACLITAXEL; ROMIDEPSIN; TRANSCRIPTOME; TRANYLCYPROMINE; TRICHOSTATIN A; UNINDEXED DRUG; VORINOSTAT; ZEBULARINE;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; BREAST CANCER; CARDIOTOXICITY; CELL CYCLE S PHASE; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; ENZYME ACTIVITY; ENZYME ASSAY; EPIGENETICS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENETIC REGULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DNA INTERACTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ACETYLATION; ANIMALS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG DISCOVERY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; METHYLATION; TRANSCRIPTOME;

EID: 83455178102     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111417871     Document Type: Review

References (97)

1. Portela A., Esteller M.. Epigenetic Modifications and Human Disease. Nat. Biotechnol. 2010 ; 28: 1057-1068
2. Kelly T. K., De Carvalho D., Jones P.. Epigenetic Modifications as Therapeutic Targets. Nat. Biotechnol. 2010 ; 28: 1069-1078
3. Yang X., Lay F., Han H., Jones P.. Targeting DNA Methylation for Epigenetic Therapy. Trends Pharmacol. Sci. 2010 ; 31: 536-546
4. Mai A.. The Therapeutic Uses of Chromatin-Modifying Agents. Expert Opin. Ther. Targets. 2007 ; 11: 835-851 (Pubitemid 46908272)
5. Meissner A.. Epigenetic Modifications in Pluripotent and Differentiated Cells. Nat. Biotechnol. 2010 ; 28: 1057-1068
6. Reik W., Lewis A.. Co-evolution of X-Chromosome Inactivation and Imprinting in Mammals. Nat. Rev. Genet. 2005 ; 6: 403-410 (Pubitemid 40577183)
7. Jin B., Tao Q., Peng J., Soo H. M., Wu W., Ying J., Fields C. R., Delmas A. L., Liu X., Qiu J., et al. DNA Methyltransferase 3B (DNMT3B) Mutations in ICF Syndrome Lead to Altered Epigenetic Modifications and Aberrant Expression of Genes Regulating Development, Neurogenesis and Immune Function. Hum. Mol. Genet. 2008 ; 17: 690-709 (Pubitemid 351292258)
8. Javierre B. M., Esteller M., Ballestar E.. Epigenetic Connections between Autoimmune Disorders and Hematological Malignancies. Trends Immunol. 2008 ; 29: 616-623
9. Karouzakis E., Gay R. E., Gay S., Neidhart M.. Epigenetic Control in Rheumatoid Arthritis Synovial Fibroblasts. Nat. Rev. Rheumatol. 2009 ; 5: 266-272
10. Mishra N., Brown D. R., Olorenshaw I. M., Kammer G. M.. Trichostatin A Reverses Skewed Expression of CD154, Interleukin-10, and Interferon-Gamma Gene and Protein Expression in Lupus T Cells. Proc. Natl. Acad. Sci. U. S. A. 2001 ; 98: 2628-2633 (Pubitemid 32209533)
11. Ordway J. M., Budiman M., Korshunova Y., Maloney R. K., Bedell J., Citek R. W., Bacher B., Peterson S., Rohlfing T., Hall J., et al. Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer. PLoS One. 2007 ; 12: 1-12
12. Fang F., Turcan S., Rimner A., Kaufman A., Giri D., Morris L. G., Shen R., Seshan V., Mo Q., Heguy A., et al. Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Sci. Transl. Med. 2011 ; 3 :
13. Rauch T., Zhong X., Wu X., Wang M., Kernstine K., Wang Z., Riggs A. D., Pfeifer G. P.. High-Resolution Mapping of DNA Hypermethylation and Hypomethylation in Lung Cancer. Proc. Natl. Acad. Sci. U. S. A. 2008 ; 105: 252-257
14. Dunwell T., Hesson L., Rauch T., Wang L., Clark R., Dallol A., Gentle D., Catchpoole D., Maher E. R., Pfeifer G. P., et al. A Genome-Wide Screen Identifies Frequently Methylated Genes in Haematological and Epithelial Cancers. Mol. Cancer. 2010 ; 9: 44
15. Issa J. P., Kantarjian H. M.. Targeting DNA Methylation. Clin. Cancer Res. 2009 ; 15: 3938-3946
16. Fenaux P., Mufti G. J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., Schoch R., Gattermann N., Sanz G., List A., et al. Efficacy of Azacitidine Compared with That of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: A Randomised, Open-Label, Phase III Study. Lancet Oncol. 2009 ; 10: 223-232
17. Yoo C. B., Cheng J. C., Jones P. A.. Zebularine: A New Drug for Epigenetic Therapy. Biochem. Soc. Trans. 2004 ; 32: 910-912 (Pubitemid 39655501)
18. Gravina G., Festuccia C., Marampon F., Popov V., Pestell R., Zani B. M., Tombolini V.. Biological Rationale for the Use of DNA Methyltransferase Inhibitors as New Strategy for Modulation of Tumor Response to Chemotherapy and Radiation. Mol. Cancer. 2010 ; 9: 305
19. Allan B., Beechem J., Lindstrom W., Reich N. O.. Direct Real Time Observation of Base Flipping by the EcoRI DNA Methyltransferase. J. Biol. Chem. 1998 ; 273: 2368-2373 (Pubitemid 28069292)
20. Horton J., Liebert K., Hattman S., Jeltsch A., Cheng X.. Transition from Nonspecific to Specific DNA Interactions along the Substrate-Recognition Pathway of Dam Methyltransferase. Cell. 2005 ; 121: 349-361 (Pubitemid 40692296)
21. Handa V., Jeltsch A.. Profound Flanking Sequence Preference of Dnmt3a and Dnmt3b Mammalian DNA Methyltransferases Shape the Human Epigenome. J. Mol. Biol. 2005 ; 348: 1103-1112 (Pubitemid 40602369)
22. Siedlecki P., Boy R. G., Comagic S., Schirrmacher R., Wiessler M., Zielenkiewicz P., Suhai S., Lyko F.. Establishment and Functional Validation of a Structural Homology Model for Human DNA Methyltransferase 1. Biochem. Biophys. Res. Commun. 2003 ; 306: 558-563 (Pubitemid 36683111)
23. Brueckner B., Boy R., Siedlecki P., Musch T., Kliem C., Zielenkiewicz P., Suhai S., Wiessler M., Lyko F.. Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases. Cancer Res. 2005 ; 65: 6305-6311 (Pubitemid 40994416)
24. Kuck D., Singh N., Lyko F., Medina-Franco J.. Novel and Selective DNA Methyltransferase Inhibitors: Docking-Based Virtual Screening and Experimental Evaluation. Bioorg. Med. Chem. 2010 ; 18: 822-829
25. RouleauN.SilvaL.RyabovI.RobyP.MarciA. In Development of a Non-Radioactive, No-Wash Biochemical Assay for High-Throughput Screening of Small Molecule Modulators of DNA Methyltransferases, Proceedings of the SBS Conference, Orlando, FL, Apr 27-31, 2011; abstract WP512. http:// perkinelmerreagents.onconfluence.com/download/attachments/328664/ DNMT+2011+SBS+Poster.pdf?version=1&modificationDate=1303753984593
26. Liebert K., Jeltsch A.. Detection and Quantitation of the Activity of DNA Methyltransferases Using a Biotin/Avidin Microplate Assay. Methods Mol Biol. 2008 ; 418: 149-156
27. Humeny A., Beck C., Becker C. M., Jeltsch A.. Detection and Analysis of Enzymatic DNA Methylation of Oligonucleotide Substrates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. Anal. Biochem. 2003 ; 313: 160-166 (Pubitemid 36268831)
28. Holz B., Klimasauskas S., Serva S., Weinhold E.. 2-Aminopurine as a Fluorescent Probe for DNA Base Flipping by Methyltransferases. Nucleic Acids Res. 1998 ; 26: 1076-1083 (Pubitemid 28291665)
29. Neely R., Daujotyte D., Grazulis S., Magennis S., Dryden D., Klimasauskas S., Jones A.. Time-Resolved Fluorescence of 2-Aminopurine as a Probe of Base Flipping in M. HhaI-DNA Complexes. Nucleic Acids Res. 2005 ; 33: 6953-6960 (Pubitemid 43125064)
30. Horton J. R., Liebert K., Bekes M., Jeltsch A., Cheng X.. Structure and Substrate Recognition of the Escherichia coli DNA Adenine Methyltransferase. J. Mol. Biol. 2006 ; 358: 559-570
31. Jurkowski T. P., Anspach N., Kulishova L., Nellen W., Jeltsch A. The M.EcoRV DNA-(Adenine N6)-Methyltransferase Uses DNA Bending for Recognition of an Expanded EcoDam Recognition Site. J. Biol. Chem. 2007 ; 282: 36942-36952
32. Youngblood B., Reich N. O.. Conformational Transitions as Determinants of Specificity for the DNA Methyltransferase EcoRI. J. Biol. Chem. 2006 ; 281: 26821-26831 (Pubitemid 44401711)
33. Ricci F., Bonham A., Mason A., Reich N. O., Plaxco K.. Reagentless, Electrochemical Approach for the Specific Detection of Double- and Single-Stranded DNA Binding Proteins. Anal. Chem. 2009 ; 81: 1608-1614
34. Bonham A., Neumann T., Tirrell M., Reich N. O.. Tracking Transcription Factor Complexes on DNA Using Total Internal Reflectance Fluorescence Protein Binding Microarrays. Nucleic Acids Res. 2009 ; 37 (13). e94
35. Lin Y., Shaw A., Wang S., Hsu C., Teng I., Huang T. H. M., Chen C.-S., Leu Y.-W., Hsiao S.-H.. Identification of Novel DNA Methylation Inhibitors via a Two-Component Reporter Gene System. J. Biomed. Sci. 2011 ; 18: 3
36. Cole P.. Chemical Probes for Histone-Modifying Enzymes. Nat. Chem. Biol. 2008 ; 4: 590-597
37. Fischle W.. Talk Is Cheap-Cross-Talk in Establishment, Maintenance, and Readout of Chromatin Modifications. Genes Dev. 2008 ; 22: 3375-3382
38. Lan F., Nottke A., Yang Shi Y.. Mechanisms Involved in the Regulation of Histone Lysine Demethylases. Curr. Opin. Cell Biol. 2008 ; 20: 316-325
39. Cloos P., Christensen J., Agger K., Helin K.. Erasing the Methyl Mark: Histone Demethylases at the Center of Cellular Differentiation and Disease. Genes Dev. 2008 ; 22: 1115-1140 (Pubitemid 351656572)
40. Jenuwein T.. The Epigenetic Magic of Histone Lysine Methylation. FEBS J. 2006 ; 273: 3121-3135
41. Grewal S. I., Jia S.. Heterochromatin Revisited. Nat. Rev. Genet. 2007 ; 8: 35-46 (Pubitemid 46006048)
42. Tachibana M., Sugimoto K., Nozaki M., Ueda J., Ohta T., Ohki M., Fukuda M., Takeda N., Niida H., Kato H., et al. G9a Histone Methyltransferase Plays a Dominant Role in Euchromatic Histone H3 Lysine 9 Methylation and Is Essential for Early Embryogenesis. Genes Dev. 2002 ; 16: 1779-1791 (Pubitemid 34803894)
43. Tachibana M., Ueda J., Fukuda M., Ohta T., Iwanari H., Sakihama T., Kodama T., Hamakubo T., Shinkai Y.. Histone Methyltransferases G9a and GLP Form Heteromeric Complexes and Are Both Crucial for Methylation of Euchromatin at H3-K9. Genes Dev. 2005 ; 19: 815-826
44. Takahashi Y., Shilatifard A.. Structural Basis for H3K4 Trimethylation by Yeast Set1/COMPASS. Adv. Enzyme Regul. 2010 ; 50 (1). 104-110
45. Li T., Kelly W. G.. A Role for Set1/MLL-Related Components in Epigenetic Regulation of the Caenorhabditis elegans Germ Line. PLoS Genet. 2011 ; 7 ( 3 ):
46. Cosgrove M., Patel A.. Mixed Lineage Leukemia: A Structure-Function Perspective of the MLL1 Protein. FEBS J. 2010 ; 277 (8). 1832-1842
47. Huang Y., Stewart T. M., Wu Y., Baylan S. B., Marton L. J., Perkins B., Jones R. J., Woster P. M., Casero R. A.. Inhibition of Lysine-Specific Demethylase 1 by Polyamine Analogues Results in Reexpression of Aberrantly Silenced Genes. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 8023-8028 (Pubitemid 47185869)
48. Anand R., Marmorstein R.. Structure and Mechanism of Lysine-Specific Demethylase Enzymes. J. Biol. Chem. 2007 ; 282: 35425-35429 (Pubitemid 350277089)
49. Forneris F., Binda C., Adamo A., Battaglioli E., Mattevi A.. Structural Basis of LSD1-CoREST Selectivity in Histone H3 Recognition. J. Biol Chem. 2007 ; 282: 20070-20074 (Pubitemid 47099979)
50. Chen Y., Yang Y., Wang F., Wan K., Yamane K., Zhang Y., Lei M.. Crystal Structure of Human Histone Lysine-Specific Demethylase 1 (LSD1). Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103: 13956-13961 (Pubitemid 44452964)
51. King O. N. F., Li X. S., Sakurai M., Kawamura A., Rose N. R., Ng S. S., Quinn A. M., Rai G., Mott B. T., Beswick P., et al. Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors. PLoS ONE. 2010 ; 5 (11). e15535
52. Li H., Ilin S., Wang W., Duncan E. M., Wysocka J., Allis C. D., Patel D. J.. Molecular Basis for Site-Specific Read-Out of Histone H3K4me3 by the BPTF PHD Finger of NURF. Nature. 2006 ; 442: 91-95 (Pubitemid 44064215)
53. Li L., Greer C., Eisenman R. N., Secombe J.. Essential Functions of the Histone Demethylase Lid. PLoS Genet. 2010 ; 6 ( 11 ):
54. Wissmann M., Yin N., Müller J. M., Greschik H., Fodor B. D., Jenuwein T., Vogler C., Schneider R., Günther T., Buettner R., et al. Cooperative Demethylation by JMJD2C and LSD1 Promotes Androgen Receptor-Dependent Gene Expression. Nat. Cell Biol. 2007 ; 9: 347-353
55. Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A.. Identification of a Specific Inhibitor of the Histone Methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005 ; 1: 143-145
56. Kubicek S., O'Sullivan R. J., August E. M., Hickey E. R., Zhang Q., Teodoro M. C., Rea S., Mechtler K., Kowalski J. A., Homon C. A., et al. Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase. Mol. Cell. 2007 ; 25 (3). 473-481 (Pubitemid 46206139)
57. Chang Y., Zhang X., Horton J. R., Upadhyay A. K., Spannhoff A., Liu J., Snyder J. P., Bedford M. T., Cheng X.. Structural Basis for G9a-Like Protein Lysine Methyltransferase Inhibition by BIX-01294. Nat. Struct. Mol. Biol. 2009 ; 16: 312-317
58. Binda C., Valente S., Romanenghi M., Pilotto S., Cirilli R., Karytinos A., Ciossani G., Botrugno O. A.. Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. J. Am. Chem. Soc. 2010 ; 132: 6827-6833
59. Rose N., Woon E. C., Kingham G. L., King O. N., Mecinović J., Clifton I. J., Ng S. S., Talib-Hardy J., Oppermann U., McDonough M. A., et al. Selective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic Approaches. J. Med. Chem. 2010 ; 53: 1810-1818
60. Caron M., Blouin J., Normand C., Labonté A., Plante H., Arcand M., Beaudet L., Padrós J.. In. Proceedings of the 102nd Annual Meeting of the AACR ; Orlando, FL ;..
61. Kawamura A., Tumber A., Rose N. R., King O. N., Daniel M., Oppermann U., Heightman T. D., Schofield C.. Development of Homogeneous Luminescence Assays for Histone Demethylase Catalysis and Binding. Anal. Biochem. 2010 ; 404: 86-93
62. Wang Z., Zang C., Cui K., Schones D. E., Barski A., Peng W., Zhao K.. Genome-Wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes. Cell. 2009 ; 138: 1019-1031
63. Grozinger C. M., Schreiber S. L.. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. Chem. Biol. 2002 ; 9: 3-16 (Pubitemid 34155860)
64. Backs J., Backs T., Bezprozvannaya S., McKinsey T., Olson E.. Histone Deacetylase 5 Acquires Calcium/Calmodulin-Dependent Kinase II Responsiveness by Oligomerization with Histone Deacetylase 4. Mol. Cell. Biol. 2008 ; 28: 3437-3445 (Pubitemid 351657105)
65. Bolger T., Yao T.. Intracellular Trafficking of Histone Deacetylase 4 Regulates Neuronal Cell Death. J. Neurosci. 2005 ; 25: 9544-9553 (Pubitemid 41464769)
66. Riccio A.. Dynamic Epigenetic Regulation in Neurons: Enzymes, Stimuli and Signaling Pathways. Nat. Neurosci. 2010 ; 13: 1330-1337
67. Meaney M., Ferguson-Smith A.. Epigenetic Regulation of the Neural Transcriptome: The Meaning of the Marks. Nat. Neurosci. 2010 ; 13: 1313-1318
68. Bolden J. E., Peart M. J., Johnstone R. W.. Anticancer Activities of Histone Deacetylase Inhibitors. Nat. Rev. Drug Discov. 2006 ; 5: 769-784 (Pubitemid 44348499)
69. Ma X., Ezzeldin H. H., Diasio R. B.. Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials. Drugs. 2009 ; 69: 1911-1934
70. Pandolfi P. P.. In Vivo Analysis of the Molecular Genetics of Acute Promyelocytic Leukemia. Oncogene. 2001 ; 20: 5726-5735 (Pubitemid 32928110)
71. Pasqualucci L., Bereschenko O., Niu H., Klein U., Basso K., Guglielmino R., Cattoretti G., Dalla-Favera R.. Molecular Pathogenesis of Non-Hodgkin's Lymphoma: The Role of Bcl-6. Leuk Lymphoma. 2003 ; 44: S5 - S12
72. Butler R., Bates G.. Histone Deacetylase Inhibitors as Therapeutics for Polyglutamine Disorders. Nat. Rev. 2006 ; 7: 784-796 (Pubitemid 44435261)
73. Gan L., Mucke L.. Paths of Convergence: Sirtuins in Aging and Neurodegeneration. Neuron. 2008 ; 58: 10-14 (Pubitemid 351467036)
74. Min S., Cho S. H., Zhou Y., Schroeder S., Haroutunian V., Seeley W. W., Huang E. J., Shen Y., Masliah E., Mukherjee C., et al. Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy. Neuron. 2010 ; 67: 953-966
75. Stimson L., Rowlands M. G., Newbatt Y. M., Smith N. F., Raynaud F. I., Rogers P., Bavetsias V., Gorsuch S., Jarman M., Bannister A., et al. Isothiazolones as Inhibitors of PCAF and p300 Histone Acetyltransferase Activity. Mol. Cancer Ther. 2005 ; 4: 1521-1532 (Pubitemid 41556434)
76. Bowers E. M., Yan G., Mukherjee C., Orry A., Wang L., Holbert M. A., Crump N. T., Hazzalin C. A., Liszczak G., Yuan H., et al. Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor. Chem. Biol. 2010 ; 17 (5). 471-482
77. Richon V. M., Sandhoff T. W., Rifkind R. A., Marks P. A.. Histone Deacetylase Inhibitor Selectively Induces p21WAF1 Expression and Gene-Associated Histone Acetylation. Proc. Natl. Acad. Sci. 2000 ; 97: 10014-10019
78. Deroanne C. F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J. M., Nusgens B. V., Castronovo V.. Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular Endothelial Growth Factor Signaling. Oncogene. 2002 ; 21: 427-436 (Pubitemid 34123805)
79. Mazieres J., Tovar D., He B., Nieto-Acosta J., Marty-Detraves C., Clanet C., Pradines A., Jablons D., Favre G.. Epigenetic Regulation of RhoB Loss of Expression in Lung Cancer. BMC Cancer. 2007 ; 7: 220
80. Haggarty S. J., Koeller K. M., Wong J. C., Grozinger C. M., Schreiber S. L.. Domain Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation. Proc. Natl. Acad. Sci. U. S. A. 2003 ; 100: 4389-4394 (Pubitemid 36457739)
81. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., Buggy J. J.. A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas. Leukemia. 2008 ; 22: 1026-1034 (Pubitemid 351689885)
82. Namdar M., Perez G., Ngo L., Marks P.. Selective Inhibition of Histone Deacetylase 6 (HDAC6) Induces DNA Damage and Sensitizes Transformed Cells to Anticancer Agents. Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 20003-20008
83. Bedalov A., Gatbonton T., Irvine W. P., Gottschling D. E., Simon J. A.. Identification of a Small Molecule Inhibitor of Sir2p. Proc. Natl. Acad. Sci. U. S. A. 2001 ; 98: 15113-15118 (Pubitemid 34013978)
84. Tervo A., Kyrylenko S., Niskanen P., Salminen A., Leppänen J., Nyrönen T. H., Järvinen T., Poso A.. An In Silico Approach to Discovering Novel Inhibitors of Human Sirtuin Type 2. J. Med. Chem. 2004 ; 47: 6292-6298 (Pubitemid 39587253)
85. Tervo A., Suuronen T., Kyrylenko S., Kuusisto E., Kiviranta P. H., Salminen A., Leppänen J., Poso A.. Discovering Inhibitors of Human Sirtuin Type 2: Novel Structural Scaffolds. J. Med. Chem. 2006 ; 49: 7239-7241 (Pubitemid 44886010)
86. Napper A., Hixon J., McDonagh T., Keavey K., Pons J. F., Barker J., Yau W. T., Amouzegh P., Flegg A., Hamelin E., et al. Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1. J. Med. Chem. 2005 ; 48: 8045-8054 (Pubitemid 41798434)
87. Hassig C., Symons K. T., Guo X., Nguyen P. M., Annable T., Wash P. L., Payne J. E., Jenkins D. A., Bonnefous C., Trotter C., et al. KD5170, a Novel Mercaptoketone-Based Histone Deacetylase Inhibitor That Exhibits Broad Spectrum Antitumor Activity In Vitro and In Vivo. Mol. Cancer Ther. 2008 ; 7 (5). 1054-1065
88. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S. C., Carey N., et al. Determination of the Class and Isoform Selectivity of Small-Molecule Histone Deacetylase Inhibitors. Biochem. J. 2008 ; 409: 581-589 (Pubitemid 351184977)
89. Niles A., Evans N., Kirkland T.. In. Proceedings of the 102nd Annual Meeting of the AACR ; Orlando, FL ;..
90. Geng L., Cuneo K., Fu A., Tu T., Atadja P., Hallahan D.. Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer. Cancer Res. 2006 ; 66: 11298-11304 (Pubitemid 46009960)
91. Esteller M.. Cancer Epigenomics: DNA Methylomes and Histone-Modification Maps. Nat. Rev. 2007 ; 8: 286-298 (Pubitemid 46439286)
92. Dormeyer W., Ott M., Schnolzer M.. Probing Lysine Acetylation in Proteins Strategies, Limitations, and Pitfall of In Vitro Acetyltransferase Assays. Mol. Cell. Proteomics. 2005 ; 4: 1226-1239 (Pubitemid 41448711)
93. Gurard-Levin Z., Kilian K., Kim J., Bahr K., Mrksich M.. Peptide Arrays Identify Isoform-Selective Substrates for Profiling Endogenous Lysine Deacetylase Activity. JACS Chem. Biol. 2010 ; 5: 863-873
94. Lee A. Y., Paweletz C. P., Pollock R. M., Settlage R. E., Cruz J. C., Secrist J. P., Miller T. A., Stanton M. G., Kral A. M., Ozerova N. D., et al. Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry. J. Proteome Res. 2008 ; 7 (12). 5177-5187
95. Bantscheff M., Hopf C., Savitski M. M., Dittmann A., Grandi P., Michon A. M., Schlegl J., Abraham Y., Becher I., Bergamini G., et al. Chemoproteomics Profiling of HDAC Inhibitors Reveals Selective Targeting of HDAC Complexes. Nat Biotechnol. 2011 ; 29 (3). 255-265
96. Comley J.. Epigenetic Screening Trends. Drug Discov. World. 2011 ; (Spring). 40-55
97. Plummer R., Vidal L., Griffin M., Lesley M., de Bono J., Coulthard S., Sludden J., Siu L. L., Chen E. X., Oza A. M., et al. Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2009 ; 15 (9). 3177-3183